EUCTR2012-002105-22-ES进行中（未招募）1 期
Personal monitoring of liver transplant patients infected with Hepatitis C Virus. Pilot study to compare the evolution of Hepatitis C by receiving immunosuppression with tacrolimus in combination with Mycophenolate Mofetil or Everolimus.
Dra Itxarone Bilbao. Servicio de cirugía hepatobiliopancreatica y trasplantes. HUVH0 个研究点目标入组 10 人开始时间: 2012年6月25日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients ? 18 years with HCV RNA-positive 12 months before transplantation, recipients of a first orthotopic liver transplantation.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 40
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Multi-organ transplant recipients or who have previously received an organ transplant. 2. Patients with split or living donor recipients. 3. Transplant recipients with ABO incompatibility. 4. Patients seropositive for HIV antibodies. 5. Recipients who receive a transplant for fulminant hepatic failure. 6. HCV patients with cirrhosis who received antiviral treatment before transplantation, and have to negative serum HCV-RNA. 7. Patients with known malignancy or history of malignancy except basal cell skin carcinoma and hepatocellular carcinoma meeting the following criteria: absence of vascular invasion, lymph single or less than two inches in diameter or two or three nodules of no more than three inches in diameter (Milan criteria). 8. Patients with a glomerular filtration <60 ml/min/1.73m 2 before transplantation or requiring renal dialysis before transplantation. 9. Patients in whom severe coexisting disease, or suffering any unstable medical condition that could affect the objectives of the study. 10. Patients who have been treated during the month prior to inclusion in the study with a drug or therapy is not recorded (investigational drug) or if such therapy be administered in the post-transplant. 11. Pregnant patients, nursing or of childbearing potential, not using effective contraception.
- •Exclusion criteria at the time of randomization (day 28 post-transplant): Patients who have not completed the healing process post-transplant month. Patients with a platelet count <50.000/mm3, a WBC count <2000/mm3, active infection requiring ICU admission or threatens vital, requiring intensive care and life support measures.
研究者
相似试验
Unknown
不适用
A Comparison of Invasive and Non-invasive Measurement of CI and SVR in Liver TransplantationLiving Donor Liver TransplantationNCT04909645Seoul National University Hospital30
招募中
不适用
Tracking the biomarker of liver transplant graft acceptance or rejection during the induction and maintenance phase of tolerance via induced T cells with suppressing function.iving Donor Liver TransplantJPRN-jRCT1030200339chida Koichiro20
招募中
不适用
Telemonitoring by renal transplantation patientsrenal transplantation10038430NL-OMON33498eids Universitair Medisch Centrum20
已完成
不适用
Monitoring Living Donor Liver Functions by ThromboelastometryTHROMBELASTOGRAPHY and Liver Graft FunctionsNCT02336191Mansoura University50
招募中
不适用
Immunemonitoring of patients scheduled for liver transplantation and resectioC22.0Liver cell carcinomaDRKS00013567Klinikum der LMU München80